HCATICKER
Hca Healthcare, Inc.
Congress has disclosed 25 buys and 28 sells of HCA (Hca Healthcare, Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.
Activity Congressional Activity
25
Buy
28
Sell
-3
Net
14
Active politicians
Round-trip watch Still on the books
Members who disclosed buying HCA and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.
| Member | Entry (last buy) | Entry price | Now | vs entry | Status |
|---|---|---|---|---|---|
| Alan Armstrong | 2026-03-27 | $470.04 | $473.19 | +0.7% | ↩ near entry |
| Jared Moskowitz | 2026-06-17 | $387.45 | $473.19 | +22.1% | in profit |
Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).
Price & congressional trades
Buy
Sell
Fundamentals · FY2026 Valuation
Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.
P/E
14.59
▼ cheaper than
Health (median 29.7)
how it's calculated
P/E = price ÷ earnings per share
$473.19 ÷ $32.44 = 14.59
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
-12.24
≈ in line with
Health (median 4.4)
how it's calculated
P/B = price ÷ book value per share
$473.19 ÷ $-38.67 = -12.24
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
Legislation Related Legislation
Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.
| Bill | Title | Policy area | Latest action |
|---|---|---|---|
| HR 10887 | Protecting Consumer Access to Generic Drugs Act of 2026 | Health | 2026-10-22 |
| HR 10874 | Medicare Low Income Subsidy Equality Act of 2026 | Health | 2026-10-22 |
| HR 10858 | CARE for Blood Cancer Act of 2026 | Health | 2026-10-22 |
| HR 10810 | National Patient Safety Board Act of 2026 | Health | 2026-10-15 |
| HR 10824 | Stroke Education and EMS Care Improvement Act of 2026 | Health | 2026-10-15 |
53 trades Recent Congressional Trades
Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.
| Politician | Chamber | Type | Owner | Date | Disclosure lag | Price move in that window | Amount | Score | Source |
|---|---|---|---|---|---|---|---|---|---|
| Jared Moskowitz | House | BUY | Child · Morgan Stanley Active Assets (5) | 2026-06-17 | 13 days | +0.4% | $1K–$15K 0.3% of NW |
27.9 | ↗ filing |
| Jared Moskowitz | House | BUY | Self · Morgan Stanley Active Assets (1) | 2026-06-17 | 13 days | +0.4% | $1K–$15K 0.3% of NW |
27.9 | ↗ filing |
| Alan Armstrong | Senate | BUY ◆ insider divergence · moderate | Self | 2026-03-27 | 116 days | -20.8% | $1K–$15K | 99.1 | ↗ eFD |
| Rohit Khanna | House | SELL OCR ◆ insider convergence · moderate | Child | 2025-12-19 | 16 days | -0.5% | $1K–$15K | 4.2 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence | Child | 2025-10-27 | 8 days | +0.8% | $1K–$15K | 4.0 | ↗ filing |
| Lisa McClain | House | SELL ◆ insider convergence | Spouse · Charles Schwab Brokerage Account 924 | 2025-09-11 | 20 days | +6.0% | $1K–$15K 0.1% of NW |
84.8 | ↗ filing |
| Lisa McClain | House | BUY ◆ insider divergence | Spouse · Charles Schwab Brokerage Account 924 | 2025-08-19 | 13 days | +0.3% | $1K–$15K 0.1% of NW |
97.4 | ↗ filing |
| Jared Moskowitz | House | BUY ◆ insider divergence | Self · Morgan Stanley Active Assets (1) | 2025-05-15 | 16 days | -1.1% | $1K–$15K 0.3% of NW |
64.6 | ↗ filing |
| Jared Moskowitz | House | BUY ◆ insider divergence | Child · Morgan Stanley Active Assets (5) | 2025-05-15 | 16 days | -1.1% | $1K–$15K 0.3% of NW |
64.6 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence | Child | 2025-05-07 | 33 days | +3.3% | $15K–$50K | 29.7 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence | Child | 2025-05-07 | 33 days | +3.3% | $1K–$15K | 12.3 | ↗ filing |
| Julie Johnson | House | SELL ◆ insider convergence | Joint · Merrill Lynch Long Term Growth | 2025-04-07 | 29 days | +8.2% | $1K–$15K <0.1% of NW |
66.4 | ↗ filing |
| Rob Bresnahan | House | SELL ◆ insider convergence | Self · JP Morgan Brokerage Account | 2025-02-25 | 0 days | 0.0% | $1K–$15K 0.2% of NW |
64.4 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence | Child | 2025-02-25 | 8 days | -4.0% | $1K–$15K | 2.6 | ↗ filing |
| Valerie Hoyle | House | SELL ◆ insider convergence · moderate | Spouse · Fidelity Rollover IRA | 2024-12-27 | 258 days | +33.7% | $1K–$15K 0.8% of NW |
30.2 | ↗ filing |
| Valerie Hoyle | House | BUY ◆ insider divergence · moderate | Spouse · Fidelity Rollover IRA | 2024-10-29 | 317 days | +12.4% | $1K–$15K 0.8% of NW |
65.6 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence · moderate | Child | 2024-10-15 | 23 days | -11.3% | $1K–$15K | 4.5 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence · moderate | Child | 2024-06-12 | 20 days | — | $1K–$15K | 5.5 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence · moderate | Joint · Morgan Stanley - Select UMA Account # 1 | 2024-03-01 | 34 days | — | $1K–$15K <0.1% of NW |
0.2 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence · moderate | Child | 2024-01-10 | 23 days | — | $1K–$15K | 6.8 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence · moderate | Child | 2023-12-05 | 30 days | — | $1K–$15K | 8.6 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-11-28 | 7 days | — | $1K–$15K <0.1% of NW |
4.5 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-11-13 | 22 days | — | $1K–$15K <0.1% of NW |
5.5 | ↗ filing |
| Rohit Khanna | House | BUY OCR | Child | 2023-11-03 | 32 days | — | $1K–$15K | 10.6 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence · moderate | Child | 2023-09-13 | 22 days | — | $1K–$15K | 15.7 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence · moderate | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-07-18 | 21 days | — | $1K–$15K <0.1% of NW |
6.8 | ↗ filing |
| Zoe Lofgren | House | SELL ◆ insider convergence · moderate | Spouse · John Marshall Collins Rollover IRA | 2023-05-25 | 12 days | — | $1K–$15K 0.1% of NW |
15.7 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence · moderate | Child | 2023-05-10 | 23 days | — | $1K–$15K | 22.3 | ↗ filing |
| Rohit Khanna | House | SELL OCR ◆ insider convergence · moderate | Child | 2023-04-12 | 21 days | — | $1K–$15K | 40.4 | ↗ filing |
| Josh Gottheimer | House | SELL ◆ insider convergence · moderate | Joint · Morgan Stanley - Select UMA Account # 1 | 2023-01-27 | 10 days | — | $1K–$15K <0.1% of NW |
8.6 | ↗ filing |
| Rohit Khanna | House | BUY OCR ◆ insider divergence · moderate | Child | 2023-01-11 | 22 days | — | $1K–$15K | 75.9 | ↗ filing |
| Susie Lee | House | SELL | Joint · DSL Living Trust > Bank of New York Brokerage Account 340 | 2022-11-30 | 5 days | — | $1K–$15K 0.2% of NW |
10.6 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint · Morgan Stanley - Select UMA Account # 1 | 2022-09-28 | 7 days | — | $1K–$15K <0.1% of NW |
10.6 | ↗ filing |
| Kathy Manning | House | SELL | Joint · Charles Schwab - O'Shaughnessy Asset Management | 2022-08-03 | 34 days | — | $1K–$15K 0.1% of NW |
40.4 | ↗ filing |
| Kathy Manning | House | BUY | Joint · Charles Schwab - O'Shaughnessy Asset Management | 2022-07-20 | 13 days | — | $1K–$15K 0.1% of NW |
75.9 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint · Morgan Stanley - Select UMA Account # 1 | 2022-06-21 | 16 days | — | $1K–$15K <0.1% of NW |
15.7 | ↗ filing |
| Zoe Lofgren | House | BUY | Spouse | 2021-09-30 | 7 days | — | $1K–$15K 0.1% of NW |
22.3 | ↗ filing |
| Zoe Lofgren | House | SELL | Spouse | 2021-08-02 | 38 days | — | $1K–$15K 0.1% of NW |
40.4 | ↗ filing |
| Susie Lee | House | BUY | Joint | 2021-06-15 | 16 days | — | $1K–$15K 0.2% of NW |
15.7 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint | 2021-03-16 | 22 days | — | $1K–$15K <0.1% of NW |
22.3 | ↗ filing |
| Susie Lee | House | SELL | Joint | 2021-02-09 | 20 days | — | $1K–$15K 0.2% of NW |
22.3 | ↗ filing |
| Josh Gottheimer | House | SELL | Joint | 2021-01-04 | 32 days | — | $1K–$15K <0.1% of NW |
40.4 | ↗ filing |
| Josh Gottheimer | House | BUY | Joint | 2020-11-16 | 22 days | — | $1K–$15K <0.1% of NW |
75.9 | ↗ filing |
| Zoe Lofgren | House | BUY | Spouse | 2020-06-15 | 22 days | — | $1K–$15K 0.1% of NW |
75.9 | ↗ filing |
| Susie Lee | House | SELL | Joint | 2020-04-07 | 24 days | — | $1K–$15K 0.2% of NW |
40.4 | ↗ filing |
| Susie Lee | House | SELL | Joint | 2020-04-03 | 28 days | — | $1K–$15K 0.2% of NW |
75.9 | ↗ filing |
| Bill Flores | House | BUY | Self | 2019-05-08 | 28 days | — | $1K–$15K | 40.4 | ↗ filing |
| Bill Flores | House | BUY | Self | 2019-03-25 | 9 days | — | $1K–$15K | 75.9 | ↗ filing |
| Alan Lowenthal | House | SELL | Spouse | 2015-11-06 | 10 days | — | $15K–$50K | 48.0 | ↗ filing |
| Alan Lowenthal | House | BUY | Spouse | 2015-08-26 | 3 days | — | $1K–$15K | 75.9 | ↗ filing |
| Alan Lowenthal | House | BUY | Spouse | 2015-08-26 | 3 days | — | $15K–$50K | 90.9 | ↗ filing |
| Michael Conaway | House | SELL | Spouse | 2015-02-09 | 3 days | — | $1K–$15K | 40.4 | ↗ filing |
| Michael Conaway | House | BUY | Spouse | 2014-12-12 | 5 days | — | $1K–$15K | 75.9 | ↗ filing |
Corporate insiders · SEC Form 4 Insider Activity
What the company's own officers and directors did in HCA — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →
15
Congress trades with insider convergence
11
…with insider divergence
62
Insider open-market trades
Of the congressional trades in HCA, 15 coincided with corporate insiders moving the same way within 60 days, and 11 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.
| Date | Insider | Role | Type | Size | Source |
|---|---|---|---|---|---|
| 2026-02-18 | McAlevey Michael R | C-suite | SELL | $904K | ↗ EDGAR |
| 2026-02-11 | Berres Jennifer | C-suite | SELL | $2.0M | ↗ EDGAR |
| 2026-02-11 | Berres Jennifer | C-suite | SELL | $2.1M | ↗ EDGAR |
| 2026-02-11 | Wyatt Christopher F. | Other | SELL | $2.0M | ↗ EDGAR |
| 2026-02-03 | Cuffe Michael S. | C-suite | SELL | $747K | ↗ EDGAR |
| 2026-02-03 | HAZEN SAMUEL N | C-suite | SELL | $7.4M | ↗ EDGAR |
| 2026-02-03 | HAZEN SAMUEL N | C-suite | SELL | $2.5M | ↗ EDGAR |
| 2026-02-03 | HAZEN SAMUEL N | C-suite | SELL | $3.7M | ↗ EDGAR |
| 2026-02-03 | HAZEN SAMUEL N | C-suite | SELL | $3.1M | ↗ EDGAR |
| 2026-02-03 | HAZEN SAMUEL N | C-suite | SELL | $2.6M | ↗ EDGAR |
| 2026-02-03 | HAZEN SAMUEL N | C-suite | SELL | $2.1M | ↗ EDGAR |
| 2026-02-03 | HAZEN SAMUEL N | C-suite | SELL | $60K | ↗ EDGAR |
| 2025-11-05 | McAlevey Michael R | C-suite | SELL | $1.8M | ↗ EDGAR |
| 2025-09-08 | Cuffe Michael S. | C-suite | SELL 10b5-1 | $1.6M | ↗ EDGAR |
| 2025-05-13 | Foster Jon M | C-suite | SELL | $5.8M | ↗ EDGAR |
| 2025-02-14 | Berres Jennifer | C-suite | SELL | $1.3M | ↗ EDGAR |
| 2025-02-14 | Berres Jennifer | C-suite | SELL | $1.7M | ↗ EDGAR |
| 2024-11-14 | Akdamar Erol R | C-suite | SELL | $1.0M | ↗ EDGAR |
| 2024-11-14 | Billington Phillip G | Other | SELL | $1.4M | ↗ EDGAR |
| 2024-11-14 | Whalen Kathleen M | C-suite | SELL | $528K | ↗ EDGAR |
| 2024-09-12 | Cuffe Michael S. | C-suite | SELL 10b5-1 | $3.2M | ↗ EDGAR |
| 2024-07-31 | Whalen Kathleen M | C-suite | SELL | $1.1M | ↗ EDGAR |
| 2024-07-29 | Wyatt Christopher F. | Other | SELL | $1.4M | ↗ EDGAR |
| 2024-07-29 | Reiner Deborah M | Other | SELL | $1.2M | ↗ EDGAR |
| 2024-07-29 | Whalen Kathleen M | C-suite | SELL | $671K | ↗ EDGAR |
Combined timeline — Congress & insiders
Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.
| Date | Who | Type | Size | |
|---|---|---|---|---|
| Congress | 2026-06-17 | Jared Moskowitz | BUY | $1K–$15K |
| Congress | 2026-06-17 | Jared Moskowitz | BUY | $1K–$15K |
| Congress | 2026-03-27 | Alan Armstrong | BUY | $1K–$15K |
| ◆ insider | 2026-02-18 | McAlevey Michael R C-suite | SELL | $904K |
| ◆ insider | 2026-02-11 | Berres Jennifer C-suite | SELL | $2.0M |
| ◆ insider | 2026-02-11 | Berres Jennifer C-suite | SELL | $2.1M |
| ◆ insider | 2026-02-11 | Wyatt Christopher F. Other | SELL | $2.0M |
| ◆ insider | 2026-02-03 | Cuffe Michael S. C-suite | SELL | $747K |
| ◆ insider | 2026-02-03 | HAZEN SAMUEL N C-suite | SELL | $7.4M |
| ◆ insider | 2026-02-03 | HAZEN SAMUEL N C-suite | SELL | $2.5M |
| ◆ insider | 2026-02-03 | HAZEN SAMUEL N C-suite | SELL | $3.7M |
| ◆ insider | 2026-02-03 | HAZEN SAMUEL N C-suite | SELL | $3.1M |
| ◆ insider | 2026-02-03 | HAZEN SAMUEL N C-suite | SELL | $2.6M |
| ◆ insider | 2026-02-03 | HAZEN SAMUEL N C-suite | SELL | $2.1M |
| ◆ insider | 2026-02-03 | HAZEN SAMUEL N C-suite | SELL | $60K |
| Congress | 2025-12-19 | Rohit Khanna | SELL | $1K–$15K |
| ◆ insider | 2025-11-05 | McAlevey Michael R C-suite | SELL | $1.8M |
| Congress | 2025-10-27 | Rohit Khanna | SELL | $1K–$15K |
| Congress | 2025-09-11 | Lisa McClain | SELL | $1K–$15K |
| ◆ insider | 2025-09-08 | Cuffe Michael S. C-suite 10b5-1 | SELL | $1.6M |
| Congress | 2025-08-19 | Lisa McClain | BUY | $1K–$15K |
| Congress | 2025-05-15 | Jared Moskowitz | BUY | $1K–$15K |
| Congress | 2025-05-15 | Jared Moskowitz | BUY | $1K–$15K |
| ◆ insider | 2025-05-13 | Foster Jon M C-suite | SELL | $5.8M |
FAQ Common questions
How much has Congress traded HCA?
25 disclosed buys and 28 sells of HCA (Hca Healthcare, Inc.) appear in official congressional financial disclosures.
Is it legal for members of Congress to trade HCA?
Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.
Where does this data come from?
Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.